ATE313625T1 - ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN - Google Patents

ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN

Info

Publication number
ATE313625T1
ATE313625T1 AT00963362T AT00963362T ATE313625T1 AT E313625 T1 ATE313625 T1 AT E313625T1 AT 00963362 T AT00963362 T AT 00963362T AT 00963362 T AT00963362 T AT 00963362T AT E313625 T1 ATE313625 T1 AT E313625T1
Authority
AT
Austria
Prior art keywords
zinc finger
finger proteins
ßfunctional
genomicsß
gene expression
Prior art date
Application number
AT00963362T
Other languages
English (en)
Inventor
Casey C Case
Lei Zhang
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Application granted granted Critical
Publication of ATE313625T1 publication Critical patent/ATE313625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00963362T 1999-09-14 2000-09-12 ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN ATE313625T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/395,448 US6599692B1 (en) 1999-09-14 1999-09-14 Functional genomics using zinc finger proteins
PCT/US2000/024897 WO2001019981A2 (en) 1999-09-14 2000-09-12 Functional genomics using zinc finger proteins

Publications (1)

Publication Number Publication Date
ATE313625T1 true ATE313625T1 (de) 2006-01-15

Family

ID=23563088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00963362T ATE313625T1 (de) 1999-09-14 2000-09-12 ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN

Country Status (10)

Country Link
US (3) US6599692B1 (de)
EP (1) EP1238067B1 (de)
JP (3) JP2003527093A (de)
KR (1) KR20020065473A (de)
AT (1) ATE313625T1 (de)
AU (1) AU778964B2 (de)
CA (1) CA2383926C (de)
DE (1) DE60025037T2 (de)
HK (1) HK1049501B (de)
WO (1) WO2001019981A2 (de)

Families Citing this family (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084885A1 (en) * 1994-01-18 2005-04-21 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) * 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US20020164575A1 (en) * 1999-09-14 2002-11-07 Sangamo Biosciences, Inc., A Delaware Corporation Gene identification
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
AU776576B2 (en) * 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
AU2002228841C1 (en) * 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
WO2002057293A2 (en) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7067617B2 (en) * 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
US20050235369A1 (en) * 2001-03-28 2005-10-20 Yen Choo Gene regulation II
JP2005500061A (ja) * 2001-08-20 2005-01-06 ザ スクリップス リサーチ インスティテュート Ｃｎｎについての亜鉛フィンガー結合ドメイン
US20040259258A1 (en) * 2001-12-07 2004-12-23 Kim Jin-Soo Regulation of prokaryotic gene expression with zinc finger proteins
CN100463962C (zh) * 2001-12-07 2009-02-25 图尔金株式会社 嵌合蛋白质的表型筛选
WO2003087341A2 (en) 2002-01-23 2003-10-23 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
AU2003262788A1 (en) * 2002-08-23 2004-03-11 Sangamo Biosciences, Inc. High-throughput screen for modulators of chromatin modifying activity
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
EP2806025B1 (de) 2002-09-05 2019-04-03 California Institute of Technology Verwendung von Zinkfingernukleasen zur Stimulierung von Gentargeting
AU2003304087A1 (en) * 2002-10-23 2004-11-26 The General Hospital Corporation Methods for producing zinc finger proteins that bind to extended dna target sequences
AU2003295692A1 (en) * 2002-11-15 2004-06-15 Sangamo Biosciences, Inc. Methods and compositions for analysis of regulatory sequences
US20060251643A1 (en) * 2002-12-09 2006-11-09 Toolgen, Inc. Regulatory zinc finger proteins
WO2005012636A1 (en) * 2003-07-31 2005-02-10 Kao Corporation Powder composition for paper manufacturing
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20090312277A1 (en) * 2004-11-19 2009-12-17 Abdelhadi Rebbaa Compositions And Methods For Reversing Or Preventing Resistance Of A Cancer Cell To A Cytotoxic Agent
EP1963499A4 (de) * 2005-11-28 2009-04-08 Scripps Research Inst Zinkfinger-bindungsdomänen für tnn
US20070154989A1 (en) * 2006-01-03 2007-07-05 The Scripps Research Institute Zinc finger domains specifically binding agc
US20070178499A1 (en) * 2006-01-06 2007-08-02 The Scripps Research Institute Specific Labeling of Protein with Zinc Finger Tags and Use of Zinc-Finger-Tagged Proteins for Analysis
JP2009532326A (ja) * 2006-02-09 2009-09-10 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質により末梢動脈疾患を処置するための方法
WO2007136685A2 (en) * 2006-05-19 2007-11-29 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
EP2027262B1 (de) 2006-05-25 2010-03-31 Sangamo Biosciences Inc. Variante foki-spaltungshälften-domänen
ES2465996T3 (es) 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
US8148129B2 (en) * 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
EP2171052B1 (de) 2007-07-12 2014-08-27 Sangamo BioSciences, Inc. Verfahren und zusammensetzung zur deaktivierung der alpha-1,6-fucosyltransferase-genexpression
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2188384B1 (de) * 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Schnelle in-vivo-identifizierung von biologisch aktiven nukleasen
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
HRP20161004T1 (hr) * 2007-09-27 2016-10-21 Dow Agrosciences Llc Tehnološki konstruirani proteini cinkovi prsti koji imaju kao cilj gene za sintazu 5-enolpiruvilshikimat-3-fosfata
EP2205752B1 (de) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen für gezielte integration
WO2009151591A2 (en) 2008-06-10 2009-12-17 Sangamo Biosciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
JP5756016B2 (ja) 2008-10-29 2015-07-29 サンガモ バイオサイエンシーズ， インコーポレイテッド グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
EP2352369B1 (de) 2008-12-04 2017-04-26 Sangamo BioSciences, Inc. Genomänderung bei ratten mithilfe von zink-finger-nukleasen
AU2010211057B2 (en) 2009-02-04 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathies
EP2408921B1 (de) 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modifikation von cxcr4 mit manipulierten zink-fingerproteinen
EP2419511B1 (de) 2009-04-09 2018-01-17 Sangamo Therapeutics, Inc. Gezielte integration in stammzellen
CA2769262C (en) 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2011049627A1 (en) 2009-10-22 2011-04-28 Dow Agrosciences Llc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
MX336846B (es) * 2010-01-22 2016-02-03 Sangamo Biosciences Inc Alteracion genomica dirigida.
ES2751916T3 (es) 2010-02-08 2020-04-02 Sangamo Therapeutics Inc Semidominios de escisión genomanipulados
EP2660318A1 (de) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Gezielte Genommodifikation mit partiell einzelsträngigen Donatormolekülen
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
HRP20200254T1 (hr) 2010-05-03 2020-05-29 Sangamo Therapeutics, Inc. Pripravci za povezivanje modula cink fingera
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
AU2011312562B2 (en) 2010-09-27 2014-10-09 Sangamo Therapeutics, Inc. Methods and compositions for inhibiting viral entry into cells
US9175280B2 (en) 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
WO2012094132A1 (en) 2011-01-05 2012-07-12 Sangamo Biosciences, Inc. Methods and compositions for gene correction
JP6214530B2 (ja) 2011-07-15 2017-10-18 ザ ジェネラル ホスピタル コーポレイション 転写活性化因子様エフェクターの組立て方法
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
CA2848417C (en) 2011-09-21 2023-05-02 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
CA3099582A1 (en) 2011-10-27 2013-05-02 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
HK1200871A1 (en) 2011-11-16 2015-08-14 Sangamo Therapeutics, Inc. Modified dna-binding proteins and uses thereof
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
AU2013259647B2 (en) 2012-05-07 2018-11-08 Corteva Agriscience Llc Methods and compositions for nuclease-mediated targeted integration of transgenes
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
US20150225734A1 (en) 2012-06-19 2015-08-13 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
EP3196301B1 (de) 2012-07-11 2018-10-17 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von monogener krankheiten
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
SG10201701601WA (en) 2012-08-29 2017-04-27 Sangamo Biosciences Inc Methods and compositions for treatment of a genetic condition
KR102357105B1 (ko) 2012-09-04 2022-02-08 더 스크립스 리서치 인스티튜트 표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들
US9914930B2 (en) 2012-09-07 2018-03-13 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
EP3789405A1 (de) 2012-10-12 2021-03-10 The General Hospital Corporation Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
EP2928303A4 (de) 2012-12-07 2016-07-13 Haplomics Inc Faktor-viii-mutationsreparatur und toleranzinduktion
EP2954042B1 (de) 2013-02-07 2017-12-06 The General Hospital Corporation Tale-transkriptionsaktivatoren
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
EP2994531B1 (de) 2013-05-10 2018-03-28 Sangamo Therapeutics, Inc. Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
JP2016521561A (ja) * 2013-06-14 2016-07-25 セレクティス 植物における非トランスジェニックのゲノム編集のための方法
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
CA3131284C (en) 2013-08-28 2023-09-19 David Paschon Compositions for linking dna-binding domains and cleavage domains
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3441468B1 (de) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
NZ746567A (en) 2013-11-04 2019-09-27 Dow Agrosciences Llc Optimal soybean loci
CN105980395A (zh) 2013-11-04 2016-09-28 美国陶氏益农公司 最优大豆座位
NZ719494A (en) 2013-11-04 2017-09-29 Dow Agrosciences Llc Optimal maize loci
UY35812A (es) 2013-11-04 2015-05-29 Dow Agrosciences Llc ?loci de maíz óptimos?.
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
DK3492593T3 (da) 2013-11-13 2021-11-08 Childrens Medical Center Nukleasemedieret regulering af genekspression
CN105940013B (zh) 2013-12-09 2020-03-27 桑格摩生物科学股份有限公司 用于治疗血友病的方法和组合物
EP3080279B1 (de) 2013-12-11 2018-09-26 Regeneron Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur gezielten modifikation eines genoms
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10072066B2 (en) 2014-02-03 2018-09-11 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
CN106459894B (zh) 2014-03-18 2020-02-18 桑格摩生物科学股份有限公司 用于调控锌指蛋白表达的方法和组合物
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
WO2015171932A1 (en) 2014-05-08 2015-11-12 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2015188056A1 (en) 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
HRP20200529T1 (hr) 2014-06-06 2020-09-04 Regeneron Pharmaceuticals, Inc. Postupci i pripravci za modificiranje ciljnog lokusa
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
SI3161128T1 (sl) 2014-06-26 2019-02-28 Regeneron Pharmaceuticals, Inc. Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
DK3169778T5 (da) 2014-07-14 2024-10-14 Univ Washington State Nanos-knockout, der eliminerer kimbaneceller
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
DK3194570T3 (da) 2014-09-16 2021-09-13 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til nukleasemedieret genommodificering og -korrektion i hæmatopoietiske stamceller
BR112017007770A2 (pt) 2014-10-15 2018-01-16 Regeneron Pharma cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
ES2947714T3 (es) 2014-12-19 2023-08-17 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso
HK1246690A1 (zh) 2015-01-21 2018-09-14 Sangamo Therapeutics, Inc. 用於鉴定高度特异性核酸酶的方法和组合物
CA2981077A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
AU2016261927B2 (en) 2015-05-12 2022-04-07 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
HK1255161A1 (zh) 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
RS65691B1 (sr) 2015-08-06 2024-07-31 Univ Missouri Svinja i ćelije rezistentne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modifikovane cd163 gene
CN108474007A (zh) 2015-08-07 2018-08-31 联邦科学技术研究组织 产生包含种系遗传修饰的动物的方法
JP6853257B2 (ja) 2015-09-23 2021-03-31 サンガモ セラピューティクス， インコーポレイテッド Ｈｔｔリプレッサー及びその使用
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
MY189674A (en) 2015-10-28 2022-02-24 Sangamo Therapeutics Inc Liver-specific constructs, factor viii expression cassettes and methods of use thereof
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
MX387420B (es) 2015-11-24 2025-03-18 Commw Scient Ind Res Org Producción de virus en cultivos celulares.
EP3380616A4 (de) 2015-11-24 2019-11-06 Commonwealth Scientific and Industrial Research Organisation Herstellung von viren in vogeleiern
BR112018012235A2 (pt) 2015-12-18 2018-12-04 Sangamo Therapeutics Inc rompimento alvejado do receptor de células de mhc
EP3389677B1 (de) 2015-12-18 2024-06-26 Sangamo Therapeutics, Inc. Gezielte zerstörung des t-zell-rezeptors
WO2017123757A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
KR20180101442A (ko) 2016-02-02 2018-09-12 상가모 테라퓨틱스, 인코포레이티드 Dna-결합 도메인 및 절단 도메인을 연결시키기 위한 조성물
CA3025523A1 (en) 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
MA45670A (fr) 2016-07-13 2019-05-22 Vertex Pharma Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
JP2019523009A (ja) 2016-07-29 2019-08-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
EP3995574A1 (de) 2016-08-24 2022-05-11 Sangamo Therapeutics, Inc. Regulierung der genexpression mit manipulierten nukleasen
KR102455249B1 (ko) 2016-08-24 2022-10-17 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3035534A1 (en) 2016-09-07 2018-03-15 Sangamo Therapeutics, Inc. Modulation of liver genes
JP7248571B2 (ja) 2016-10-05 2023-03-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド ＭｅＣＰ２が破壊された誘導多能性幹細胞からの成熟系列の生成
JP7623784B2 (ja) 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
WO2018081775A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
IL266862B2 (en) 2016-12-01 2024-01-01 Sangamo Therapeutics Inc Tau modulators and methods and preparations for their administration
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
EP3551754B1 (de) 2016-12-08 2023-08-30 Case Western Reserve University Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
RU2019126483A (ru) 2017-01-23 2021-02-24 Ридженерон Фармасьютикалз, Инк. Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Unterdrückung von schmerzen durch geneditierung
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
LT3615674T (lt) 2017-04-28 2024-09-25 The Regents Of The University Of Colorado, A Body Corporate Reumatoidinio artrito gydymo būdai, naudojant nukreipiančios rnr hla geno redagavimą genome
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CN111164211B (zh) 2017-07-18 2024-08-02 杰特贝林基因治疗股份有限公司 用于治疗β-血红蛋白病的组合物和方法
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
AU2018313167A1 (en) 2017-08-08 2020-02-27 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
LT3675623T (lt) 2017-08-29 2025-09-10 KWS SAAT SE & Co. KGaA Patobulintas mėlynasis aleuronas ir kitos segregacijos sistemos
EP3676376B1 (de) 2017-08-30 2025-01-15 President and Fellows of Harvard College Hocheffiziente baseneditoren mit gam
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
BR112020008568A2 (pt) 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
EP3717505A4 (de) 2017-12-01 2021-12-01 Encoded Therapeutics, Inc. Gentechnisch veränderte dna-bindende proteine
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
BR112020013626A2 (pt) 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated compostos de quinoxalinona, composições, métodos e kits para aumentar a eficiência de edição de genoma
MA51619A (fr) 2018-01-17 2021-04-14 Vertex Pharma Inhibiteurs de la protéine kinase dépendante de l'adn
JP7466448B2 (ja) 2018-01-17 2024-04-12 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ－ｐｋ阻害剤
CA3089587A1 (en) 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases
US20210037798A1 (en) 2018-03-20 2021-02-11 Tsinghua University Alzheimers disease animal model and use thereof
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MA52207A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
KR20250133482A (ko) 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CA3108281A1 (en) 2018-08-03 2020-02-06 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
AU2019326408A1 (en) 2018-08-23 2021-03-11 Sangamo Therapeutics, Inc. Engineered target specific base editors
WO2020051283A1 (en) 2018-09-05 2020-03-12 The Regents Of The University Of California Generation of heritably gene-edited plants without tissue culture
KR20210060533A (ko) 2018-09-18 2021-05-26 상가모 테라퓨틱스, 인코포레이티드 프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
WO2020072677A1 (en) 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220282275A1 (en) 2018-11-15 2022-09-08 The Broad Institute, Inc. G-to-t base editors and uses thereof
EP3886869A4 (de) 2018-11-28 2022-07-06 Forty Seven, Inc. Genetisch modifizierte ablationsresistente hspcs
US12390812B2 (en) 2018-12-19 2025-08-19 Nuclein, Llc Apparatus and methods for molecular diagnostics
KR102925054B1 (ko) 2018-12-20 2026-02-10 리제너론 파마슈티칼스 인코포레이티드 뉴클레아제-매개 반복부 팽창
EP3908291A4 (de) 2019-01-07 2023-01-11 Dana-Farber Cancer Institute, Inc. Niedermolekulare degrader von fkbp12 über rekrutierung der von-hippel-lindau-e3-ubiquitin-ligase (vhl) und verwendung in dtag-systemen
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US11866469B2 (en) 2019-02-06 2024-01-09 Klogenix Llc DNA binding proteins and uses thereof
AU2019428629A1 (en) 2019-02-06 2021-01-28 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CA3132167A1 (en) 2019-04-02 2020-10-08 Weston P. MILLER IV Methods for the treatment of beta-thalassemia
AU2020256225B9 (en) 2019-04-03 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
RU2771374C1 (ru) 2019-04-04 2022-05-04 Редженерон Фармасьютикалс, Инк. Способы для бесшовного внесения целевых модификаций в направленные векторы
KR102661779B1 (ko) 2019-04-04 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물
CA3136119A1 (en) 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
TW202521561A (zh) 2019-04-23 2025-06-01 美商聖加莫治療股份有限公司 染色體9開放讀框72基因表現之調節子及其用途
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
PL3976798T3 (pl) 2019-05-29 2026-04-07 Encoded Therapeutics, Inc. Kompozycje i sposoby selektywnej regulacji genów
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
CN113906134B (zh) 2019-06-14 2025-06-24 瑞泽恩制药公司 Tau蛋白病模型
US20220267732A1 (en) 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021087361A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
US20210130828A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Gin recombinase variants
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
US20230086199A1 (en) 2019-11-26 2023-03-23 The Broad Institute, Inc. Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
EP4100519A2 (de) 2020-02-05 2022-12-14 The Broad Institute, Inc. Adeninbaseneditoren und verwendungen davon
CN116209756A (zh) 2020-03-04 2023-06-02 旗舰先锋创新Vi有限责任公司 调控基因组的方法和组合物
KR20230004456A (ko) 2020-03-04 2023-01-06 리제너론 파아마슈티컬스, 인크. 면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
EP4114951A4 (de) 2020-03-05 2024-05-08 The Regents Of The University Of California Verfahren zur herstellung von pflanzen mit minimiertem biomassenebenprodukt und zugehörige pflanzen davon
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
EP4143315A1 (de) 2020-04-28 2023-03-08 The Broad Institute Inc. <smallcaps/>?ush2a? ?gezielte basisbearbeitung eines thegens
EP4146284A1 (de) 2020-05-06 2023-03-15 Cellectis S.A. Verfahren zur genetischen modifizierung von zellen zur freisetzung therapeutischer proteine
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
US12152251B2 (en) 2020-08-25 2024-11-26 Kite Pharma, Inc. T cells with improved functionality
EP4240756A1 (de) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Zellen zur expression eines chimären rezeptors aus einem modifizierten invarianten kettenlocus der cd3-immunglobulin-superfamilie und zugehörige polynukleotide und verfahren
US20240000051A1 (en) 2020-11-16 2024-01-04 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
JP2024501971A (ja) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Ｃａｒ－ｔ活性を調節するための方法及び組成物
EP4277933A4 (de) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Sekretierbare nutzlastregulierung
CA3208612A1 (en) 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
EP4341392A4 (de) 2021-05-14 2025-02-19 Becton Dickinson and Company Multiplexiertes unvorgespanntes nukleinsäureamplifikationsverfahren
AU2022272723A1 (en) 2021-05-14 2023-11-30 Becton, Dickinson And Company Methods for making libraries for nucleic acid sequencing
US20240226164A1 (en) 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
EP4384598A1 (de) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung komplementvermittelter entzündungsreaktionen
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
AU2022327174A1 (en) 2021-08-11 2024-02-15 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023023553A2 (en) * 2021-08-17 2023-02-23 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems, and methods for activating and silencing gene expression
WO2023035011A1 (en) 2021-09-03 2023-03-09 North Carolina State University Compositions and methods for conferring resistance to geminivirus
CA3230629A1 (en) 2021-09-08 2023-03-16 Beam Therapeutics Inc. Viral guide rna delivery
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US20250313861A1 (en) 2021-10-22 2025-10-09 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
US20250064032A1 (en) 2021-12-10 2025-02-27 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN119072319A (zh) 2021-12-23 2024-12-03 萨那生物技术股份有限公司 用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
AU2022424002A1 (en) 2021-12-29 2024-06-13 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
EP4479416A1 (de) 2022-02-17 2024-12-25 Sana Biotechnology, Inc. Manipulierte cd47-proteine und verwendungen davon
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
US20250302994A1 (en) 2022-05-09 2025-10-02 Synteny Therapeutics, Inc. Erythroparvovirus with a modified genome for gene therapy
WO2023220040A1 (en) 2022-05-09 2023-11-16 Synteny Therapeutics, Inc. Erythroparvovirus with a modified capsid for gene therapy
EP4522201A1 (de) 2022-05-09 2025-03-19 Synteny Therapeutics, Inc. Erythroparvoviruszusammensetzungen und verfahren zur gentherapie
US20250302998A1 (en) 2022-05-09 2025-10-02 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
JP2025525745A (ja) 2022-08-05 2025-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｄｐ－４３の凝集耐性バリアント
WO2024040083A1 (en) 2022-08-16 2024-02-22 The Broad Institute, Inc. Evolved cytosine deaminases and methods of editing dna using same
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
KR20250116795A (ko) 2022-11-14 2025-08-01 리제너론 파마슈티칼스 인코포레이티드 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024155745A1 (en) 2023-01-18 2024-07-25 The Broad Institute, Inc. Base editing-mediated readthrough of premature termination codons (bert)
WO2024163615A1 (en) 2023-02-02 2024-08-08 University Of Florida Research Foundation, Incorporated Brain-derived neurotrophic factor-nano luciferase transgenic rodents and methods of use thereof
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー３エス２ ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
WO2024187174A2 (en) 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
US12383615B2 (en) 2023-03-23 2025-08-12 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
EP4713027A1 (de) 2023-05-16 2026-03-25 Omega Therapeutics, Inc. Verfahren und zusammensetzungen zur modulation der methylierung eines zielgens
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
EP4716541A2 (de) 2023-05-22 2026-04-01 Sana Biotechnology, Inc. Verfahren zur abgabe von inselzellen und zugehörige verfahren
CN121729237A (zh) 2023-06-30 2026-03-24 武田药品工业株式会社 Htt阻遏物及其用途
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
AU2024335327A1 (en) 2023-09-01 2026-03-26 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025064469A1 (en) 2023-09-18 2025-03-27 Omega Therapeutics, Inc. Methods for assessing dosage for epigenetic modifying agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2025194124A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids
WO2025235388A1 (en) 2024-05-06 2025-11-13 Regeneron Pharmaceuticals, Inc. Transgene genomic identification by nuclease-mediated long read sequencing
WO2025235563A1 (en) 2024-05-07 2025-11-13 Omega Therapeutics, Inc. Epigenetic modulation for upregulation of genes
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2026072529A1 (en) 2024-09-24 2026-04-02 University Of Florida Research Foundation, Incorporated Mettl7a for improved embryo competence
WO2026072421A2 (en) 2024-09-27 2026-04-02 The Broad Institute, Inc. Base editing methods and compositions for editing prnp in the treatment of prion disease
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3410650A1 (de) 1984-03-23 1985-10-03 Kernforschungsanlage Jülich GmbH, 5170 Jülich Mit mikroorganismen bewachsene poroese anorganische traeger, verfahren zur immobilisierung von mikroorganismen und dafuer geeignete traegerkoerper
US5455170A (en) 1986-08-22 1995-10-03 Hoffmann-La Roche Inc. Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05
US5317090A (en) 1987-12-16 1994-05-31 Institut Pasteur Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human hepatocellular carcinoma, and which is a retinoic acid receptor
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5340739A (en) 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990007517A1 (en) 1988-12-23 1990-07-12 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US4990607A (en) 1989-03-14 1991-02-05 The Rockefeller University Alteration of gene expression in plants
ATE166360T1 (de) 1989-03-17 1998-06-15 Salk Inst For Biological Studi Zusammensetzung und testverfahren eines elementes als antwort auf ein hormon
JP3393867B2 (ja) 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
US5578482A (en) 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DK0552202T3 (da) 1990-09-21 1996-06-03 Salk Inst For Biological Studi Fremgangsmåder medieret af det protoonkogene proteinkompleks AP-1
US5348864A (en) 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5324818A (en) 1991-08-21 1994-06-28 The Regents Of The University Of Michigan Proteins useful in the regulation of κB-containing genes
US5243041A (en) 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5302519A (en) 1991-09-09 1994-04-12 Fred Hutchinson Cancer Research Center Method of producing a Mad polypeptide
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5792640A (en) 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5916794A (en) 1992-04-03 1999-06-29 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5324638A (en) 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
DE69534629D1 (de) 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
US5376630A (en) * 1994-03-17 1994-12-27 International Flavors & Fragrances Inc. Methyl, substituted propyl-substituted pentamethyl indane derivatives, processes for producing same and perfumery uses thereof
WO1996006110A1 (en) 1994-08-18 1996-02-29 Gilman, Michael, Z. Composite dna-binding proteins and materials and methods relating thereto
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
DE4435919C1 (de) 1994-10-07 1995-12-07 Deutsches Krebsforsch Zinkfinger-DNA, -Protein und ihre Verwendung
US5871902A (en) 1994-12-09 1999-02-16 The Gene Pool, Inc. Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids
US5702914A (en) 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
AU5445296A (en) 1995-04-12 1996-10-30 Cheng Cheng Methods for preparing dna-binding proteins
DK0877752T3 (da) 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
FR2752734B1 (fr) 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5939538A (en) * 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
EP1046034A1 (de) 1998-01-09 2000-10-25 Cubist Pharmaceuticals, Inc. Verfahren zur identifizierung von ziel und test kombinationen
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
US5972615A (en) 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
WO1999041371A1 (en) 1998-02-13 1999-08-19 Genetrace Systems, Inc. Use of ribozymes for functionating genes
KR20010041088A (ko) 1998-02-20 2001-05-15 게놈 다이내믹스 인코포레이티드 아연-핑거 클래스의 ｄｎａ-결합 단백질의 디자인 방법
ES2341926T3 (es) 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
CA2323064C (en) 1998-03-17 2011-05-31 Gendaq Limited Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20020164575A1 (en) * 1999-09-14 2002-11-07 Sangamo Biosciences, Inc., A Delaware Corporation Gene identification

Also Published As

Publication number Publication date
WO2001019981A3 (en) 2002-07-11
US20020081614A1 (en) 2002-06-27
US20040203064A1 (en) 2004-10-14
JP5832787B2 (ja) 2015-12-16
US6777185B2 (en) 2004-08-17
KR20020065473A (ko) 2002-08-13
JP2003527093A (ja) 2003-09-16
HK1049501B (en) 2006-04-07
WO2001019981A2 (en) 2001-03-22
AU778964B2 (en) 2004-12-23
HK1049501A1 (en) 2003-05-16
CA2383926A1 (en) 2001-03-22
JP2011244818A (ja) 2011-12-08
JP2014144000A (ja) 2014-08-14
US6599692B1 (en) 2003-07-29
DE60025037D1 (de) 2006-01-26
EP1238067B1 (de) 2005-12-21
DE60025037T2 (de) 2006-08-17
EP1238067A2 (de) 2002-09-11
US7235354B2 (en) 2007-06-26
AU7478700A (en) 2001-04-17
CA2383926C (en) 2008-09-09

Similar Documents

Publication Publication Date Title
ATE313625T1 (de) ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN
ATE309536T1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ATE320500T1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
DE69534629D1 (de) Derivate von zinkfingerproteinen und methoden
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
DE60041452D1 (de) CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN
EP1649006A4 (de) Exo-spezifische amylase-polypeptide, diese polypeptide codierende nukleinsäuren und verwendungen davon
ATE492644T1 (de) Transfer von mrna unter verwendung von polykationischen verbindungen
DK1334200T3 (da) Multipelt inducerbart genreguleringssystem
DE69932813D1 (de) Nukleinsäurebindungsproteine
DE60138404D1 (de) Verbessertes system zur regulation der transgenexpression
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
DE60210970D1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
DK1082415T3 (da) Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC
ATE380245T1 (de) Gen von alteromonas
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
ATE382691T1 (de) Regulation der genexpression unter verwendung von einkettigen, monomeren, liganden-abhängigen polypeptidschaltern
WO2004096833A3 (en) Inducers of recombinant protein expression
ATE219515T1 (de) Methoden und reagenzien zur regulierung von apoptosis
ATE469171T1 (de) Neue insektizide proteine von bazillus thuringiensis
DE60044488D1 (de) Plasmidvektor
WO2000066735A3 (en) Human ion channel proteins
ATE273394T1 (de) Wirts-vektor-systeme zur phosphatregulierten überproduktion von polypeptiden in bacillus
ATE425260T1 (de) Rekombinante biotincarboxylasedomänen zur identifizierung von acetyl-coa-carboxylase- inhibitoren
DE60128950D1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties